Adial Pharma Q1 net loss $2M; cash $4.6M; FDA policy shift may aid AD04 path

ADIAL PHARMACEUTICALS, INC.

2026-Q1 EPS reported -$1.48 vs consensus -$2.78 ▲ beat (+46.9%)

Cash $4.6M as of Mar 31, 2026, down from $5.9M at Dec 31, 2025; runway into H2 2026.
Net loss $2.0M vs $2.2M YoY; R&D expenses down 42% to $433K; G&A up 3% to $1.6M.
FDA signals possible single pivotal trial for AD04; bipartisan AUD legislation introduced.
Established collaboration framework with Molteni Farmaceutici for European commercial pathway.
International patent application published; if granted, AD04 protection extended to 2045.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ADIAL PHARMACEUTICALS, INC. reported first quarter ended March 31, 2026 results: net income $2.0 million.

Period: first quarter ended March 31, 2026
Net income: $2.0 million
Result: reported results

Exact text from the filing

Net Loss was $2.0 million for the three months ended March 31, 2026, compared to a net loss of $2.2 million for the three months ended March 31, 2025.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

ADIAL PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-054219

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.